Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies...
Total Rounds: 5 Immuneel
| S.No. | Date | Round Name | Amount | TTM Revenue | Investors & Facilitators |
|---|---|---|---|---|---|
| 1. | Jun 8, 2026 | Series B | ₹100 Cr | ₹4.2 Cr | Inst: Singularity AMC, Rainmatter, Eight Roads Ventures, F-Prime Capital Angel: Kiran |
| 2. | Jun 24, 2024 | Series A | ₹100 Cr | ₹4.2 Cr | Inst: Taiba Healthcare |
| 3. | Apr 11, 2022 | Series A | ₹114 Cr | ₹1.1 Cr | Inst: Eight Roads Ventures, True North Venture Partners, F-Prime Capital, Khosla Ventures, Beta Operators Fund, Kotak Mahindra Bank, GLENTEC, Apollo Hospitals, True North Angel: Pankaj, Guljit |
| 4. | Sep 17, 2020 | Series A | ₹10 Cr | ₹1.9 Cr | Inst: Kotak Mahindra Bank Angel: Pankaj |
| 5. | Nov 20, 2019 | Series A | ₹79 Cr | - | Inst: Eight Roads Ventures, Sister Fund Rva, F-Prime Capital, Khosla Ventures, Apollo Hospitals, GLENTEC, Stempeutics, Syngene, Kateel Software, Beta Operators Fund, Karuna Business Solutions Angel: Bhairavi, Pankaj, Guljit, Sachin |
| Detailed Income Statement | FY 24-25 (in Cr) |
|---|---|
| 9.9 | |
| 50.4 | |
| Total profit before prior period items, exceptional items, extraordinary items and tax | (40.5) |
| Exceptional items before tax | 0 |
| Total profit before extraordinary items and tax | (40.5) |
| Extraordinary items before tax | 0 |
| Total profit before tax | (40.5) |
| 0 | |
| Total profit (loss) for period from continuing operations | (40.5) |
| Profit (loss) from discontinuing operations before tax | 0 |
| Tax expense of discontinuing operations | 0 |
| Total profit (loss) from discontinuing operation after tax | 0 |
| Total profit (loss) for period | (40.5) |
| Basic earning per equity share before extraordinary items | (0.0) |
| Diluted earnings per equity share before extraordinary items | (0.0) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 24-25 (in Cr) |
|---|---|
| 128.8 | |
| 128.8 |
| Detailed Cash Flow Statement | FY 24-25 (in Cr) |
|---|
| Detailed Income Statement | FY 23-24 (in Cr) |
|---|---|
| 2.2 | |
| 56.0 | |
| Total profit before prior period items, exceptional items, extraordinary items and tax | (53.8) |
| Exceptional items before tax | 0 |
| Total profit before extraordinary items and tax | (53.8) |
| Extraordinary items before tax | 0 |
| Total profit before tax | (53.8) |
| 0 | |
| Total profit (loss) for period from continuing operations | (53.8) |
| Profit (loss) from discontinuing operations before tax | 0 |
| Tax expense of discontinuing operations | 0 |
| Total profit (loss) from discontinuing operation after tax | 0 |
| Total profit (loss) for period | (53.8) |
| Basic earning per equity share before extraordinary items | (0.0) |
| Diluted earnings per equity share before extraordinary items | (0.0) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 23-24 (in Cr) |
|---|---|
| 71.5 | |
| 71.5 |
| Detailed Cash Flow Statement | FY 23-24 (in Cr) |
|---|
| Detailed Income Statement | FY 22-23 (in Cr) |
|---|---|
| 4.3 | |
| 43.4 | |
| Total profit before prior period items, exceptional items, extraordinary items and tax | (39.2) |
| Exceptional items before tax | 0 |
| Total profit before extraordinary items and tax | (39.2) |
| Extraordinary items before tax | 0 |
| Total profit before tax | (39.2) |
| 0 | |
| Total profit (loss) for period from continuing operations | (39.2) |
| Profit (loss) from discontinuing operations before tax | 0 |
| Tax expense of discontinuing operations | 0 |
| Total profit (loss) from discontinuing operation after tax | 0 |
| Total profit (loss) for period | (39.2) |
| Basic earning per equity share before extraordinary items | (0.0) |
| Diluted earnings per equity share before extraordinary items | (0.0) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 22-23 (in Cr) |
|---|---|
| 134.7 | |
| 134.7 |
| Detailed Cash Flow Statement | FY 22-23 (in Cr) |
|---|
| Detailed Income Statement | FY 21-22 (in Cr) |
|---|---|
| 0.8 | |
| 31.7 | |
| Total profit before prior period items, exceptional items, extraordinary items and tax | (30.9) |
| Exceptional items before tax | 0 |
| Total profit before extraordinary items and tax | (30.9) |
| Extraordinary items before tax | 0 |
| Total profit before tax | (30.9) |
| 0 | |
| Total profit (loss) for period from continuing operations | (30.9) |
| Profit (loss) from discontinuing operations before tax | 0 |
| Tax expense of discontinuing operations | 0 |
| Total profit (loss) from discontinuing operation after tax | 0 |
| Total profit (loss) for period | (30.9) |
| Basic earning per equity share before extraordinary items | (0.0) |
| Diluted earnings per equity share before extraordinary items | (0.0) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 21-22 (in Cr) |
|---|---|
| 114.4 | |
| 114.4 |
| Detailed Cash Flow Statement | FY 21-22 (in Cr) |
|---|
| Detailed Income Statement | FY 20-21 (in Cr) |
|---|---|
| 3.1 | |
| 19.5 | |
| Total profit before prior period items, exceptional items, extraordinary items and tax | (16.4) |
| Exceptional items before tax | 0 |
| Total profit before extraordinary items and tax | (16.4) |
| Extraordinary items before tax | 0 |
| Total profit before tax | (16.4) |
| (0.0) | |
| Total profit (loss) for period from continuing operations | (16.4) |
| Profit (loss) from discontinuing operations before tax | 0 |
| Tax expense of discontinuing operations | 0 |
| Total profit (loss) from discontinuing operation after tax | 0 |
| Total profit (loss) for period | (16.4) |
| Basic earning per equity share before extraordinary items | (0.0) |
| Diluted earnings per equity share before extraordinary items | (0.0) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 20-21 (in Cr) |
|---|---|
| 75.3 | |
| 75.3 |
| Detailed Cash Flow Statement | FY 20-21 (in Cr) |
|---|
| Detailed Income Statement | FY 19-20 (in Cr) |
|---|---|
| 0.7 | |
| 5.5 | |
| Total profit before prior period items, exceptional items, extraordinary items and tax | (4.8) |
| Exceptional items before tax | 0 |
| Total profit before extraordinary items and tax | (4.8) |
| Extraordinary items before tax | 0 |
| Total profit before tax | (4.8) |
| 0.0 | |
| Total profit (loss) for period from continuing operations | (4.8) |
| Profit (loss) from discontinuing operations before tax | 0 |
| Tax expense of discontinuing operations | 0 |
| Total profit (loss) from discontinuing operation after tax | 0 |
| Total profit (loss) for period | (4.8) |
| Basic earning per equity share before extraordinary items | (0.0) |
| Diluted earnings per equity share before extraordinary items | (0.0) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 19-20 (in Cr) |
|---|---|
| 76.7 | |
| 76.7 |
| Detailed Cash Flow Statement | FY 19-20 (in Cr) |
|---|
| Detailed Income Statement | FY 18-19 (in Cr) |
|---|---|
| 0 | |
| 0.2 | |
| Total profit before prior period items, exceptional items, extraordinary items and tax | (0.2) |
| Exceptional items before tax | 0 |
| Total profit before extraordinary items and tax | (0.2) |
| Extraordinary items before tax | 0 |
| Total profit before tax | (0.2) |
| 0 | |
| Total profit (loss) for period from continuing operations | (0.2) |
| Profit (loss) from discontinuing operations before tax | 0 |
| Tax expense of discontinuing operations | 0 |
| Total profit (loss) from discontinuing operation after tax | 0 |
| Total profit (loss) for period | (0.2) |
| Basic earning per equity share before extraordinary items | 0.0 |
| Diluted earnings per equity share before extraordinary items | 0 |
| Basic earning per equity share | 0.0 |
| Diluted earnings per equity share | 0 |
| Detailed Balance Sheet | FY 18-19 (in Cr) |
|---|---|
| 0.0 | |
| 0.0 |
| Detailed Cash Flow Statement | FY 18-19 (in Cr) |
|---|
As of Jun 24, 2024 • Immuneel
| Shareholder | Category | Shares (Mn) | % Holding |
|---|---|---|---|
| Taiba Healthcare | Enterprise | 0.01M | 17.01% |
| ESOP Pool Available | ESOP Pool | 0.00M | 8.34% |
| Syngene | Enterprise | 0.00M | 7.19% |
| Eight Roads Ventures India III LP | Fund | 0.00M | 6.35% |
| Siddhartha Mukherjee | Founder | 0.00M | 6.03% |
